A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Low-dose Cytarabine (LDAC) or Decitabine in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The goal of this clinical research study is to learn if combining BP1001 with the standard-of-care drug cytarabine can help control the disease in patients with AML.
Disease Group: Other diseases of blood and blood-forming organs
Treatment Agent: BP-100-1.01
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Bio-Path Holdings, Inc.
IRB Review and Approval Date: 03/13/2017
Recruitment Status: Open
Projected Accrual: 56 (from up to 12 sites in the United States, including MD Anderson)
Information and next steps
Other diseases of blood and blood-forming organs
For general questions about clinical trials: